In conclusion, this prospective pilot study provides evidence supporting the hypothesis that MCP-1 levels are elevated during the acute phase of ischemic stroke and these findings strengthen the need for further investigation through multicenter studies to evaluate the potential utility of MCP-1 as a biomarker in AIS. This evidence concerns the gene CCL2 and ischemic stroke.